AMAG Pharmaceuticals Inc
Most Recent
Amazon Dealt with Regulators Last Week
Amazon, Apple, Google, and Facebook have been fending off probes about corporate governance policy for managing user data.
Spectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.
Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Makena Auto Injector Is a Key Asset for Antares Pharma in 2018
In H1 2018, Antares Pharma (ATRS) reported revenues of $6.7 million from its Makena product.
Label Expansion of Ferahame Bodes Well for AMAG Pharmaceuticals
AMAG’s revenues from Ferahame grew at a higher pace to $26 million in 3Q17 from $22.2 million in 3Q16.
A Look at AMAG Pharmaceuticals’ Collaborations
AMAG Pharmaceuticals’ business strategy includes the expansion of its portfolio through licensing and acquisitions of additional pharmaceutical products.
How Does Incyte’s Valuation Compare to Its Peers?
In this series, we’ll look at the performance of Incyte’s existing products and other factors that are driving the company’s revenues and valuation.
How Does Incyte’s Valuation Compare to Peers?
Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.